Evaluation of palliative therapy, alone or in combination with toceranib phosphate, in dogs diagnosed with metastatic or recurrent beta-cell neoplasia

References

• Anonymous. Veterinary cooperative oncology group - common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.1. Veterinary and Comparative Oncology 14, 417–46, 2016
   PubMed Web of Science ®Google Scholar
• Bernabe LF, Portela R, Nguyen S, Kisseberth WC, Pennell M, Yancey MF, London CA. Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose. BMC Veterinary Research 9, 190, 2013
   PubMed Web of Science ®Google Scholar
• Buishand FO, Kik M, Kirpensteijn J. Evaluation of clinico-pathological criteria and the Ki67 index as prognostic indicators in canine insulinoma. The Veterinary Journal 185, 62–7, 2010
   PubMed Web of Science ®Google Scholar
• Carlsten KS, London CA, Haney S, Burnett R, Avery AC, Thamm DH. Multicenter prospective trial of hypofractionated radiation treatment, toceranib, and prednisone for measurable canine mast cell tumors. Journal of Veterinary Internal Medicine 26, 135–41, 2012
   PubMed Web of Science ®Google Scholar
• Flesner BK, Fletcher JM, Smithee T, Boudreaux B. Long-term survival and glycemic control with toceranib phosphate and prednisone for a metastatic canine insulinoma. Journal of the American Animal Hospital Association 55, e55105, 2019
   PubMed Web of Science ®Google Scholar
• Freeman L, Becvarova I, Cave N, MacKay C, Nguyen P, Rama B, Takashima G, Tiffin R, Tsjimoto H, van Beukelen P. WSAVA nutritional assessment guidelines. Journal of Feline Medicine and Surgery 13, 516–25, 2011
   PubMed Web of Science ®Google Scholar
• Gartner W, Mineva I, Daneva T, Baumgartner-Parzer S, Niederle B, Vierhapper H, Weissel M, Wagner L. A newly identified RET proto-oncogene polymorphism is found in a high number of endocrine tumor patients. Human Genetics 117, 143–53, 2005
   PubMed Web of Science ®Google Scholar
• London C, Mathie T, Stingle N, Clifford C, Haney S, Klein MK, Beaver L, Vickery K, Vail DM, Hershey B, et al. Preliminary evidence for biologic activity of toceranib phosphate (Palladia®) in solid tumours. Veterinary and Comparative Oncology 10, 194–205, 2012
   PubMed Web of Science ®Google Scholar
• London CA. Small molecule inhibitors in veterinary oncology practice. Veterinary Clinics of North America: Small Animal Practice 44, 893–908, 2014
   PubMed Web of Science ®Google Scholar
• London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP, Henry CJ, Mitchener KL, Klein MK, Hintermeister JG, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clinical Cancer Research 15, 3856–865, 2009
   PubMed Web of Science ®Google Scholar
• Moore AS, Nelson RW, Henry CJ, Rassnick KM, Kristal O, Ogilvie GK, Kintzer P. Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989–1999). Journal of the American Veterinary Medical Association 221, 811–18, 2002
   PubMed Web of Science ®Google Scholar
• Musser ML, Taikowski KL, Johannes CM, Bergman PJ. Retrospective evaluation of toceranib phosphate (Palladia) use in the treatment of inoperable, metastatic, or recurrent canine pheochromocytomas: 5 dogs (2014–2017). BMC Veterinary Research 14, 272, 2018
   PubMed Web of Science ®Google Scholar
• *Nelson RW. Beta-cell neoplasia: insulinoma. In: Feldman EC, Nelson RW, Reusch CE, Scott-Moncrieff JCR (eds). Canine and Feline Endocrinology. 4th Edtn. Pp 348–75. Saunders, St. Louis, MO, USA, 2015
   Google Scholar
• Northrup NC, Rassnick KM, Gieger TL, Kosarek CE, McFadden CW, Rosenberg MP. Prospective evaluation of biweekly streptozotocin in 19 dogs with insulinoma. Journal of Veterinary Internal Medicine 27, 483–90, 2013
   PubMed Web of Science ®Google Scholar
• Pitchaimani V, Arumugam S, Thandavarayan RA, Karuppagounder V, Afrin MR, Sreedhar R, Harima M, Nakamura M, Watanabe K. Brain adaptations of insulin signaling kinases, GLUT 3, p-BADser155 and nitrotyrosine expression in various hypoglycemic models of mice. Neurochemistry International 137, 104745, 2020
   PubMed Web of Science ®Google Scholar
• Polton GA, White RN, Brearley MJ, Eastwood JM. Improved survival in a retrospective cohort of 28 dogs with insulinoma. Journal of Small Animal Practice 48, 151–6, 2007
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Gadea BB, Wang HW, Gocheva V, Hunter KE, Tang LH, Joyce JA. Deficiency of the macrophage growth factor CSF-1 disrupts pancreatic neuroendocrine tumor development. Oncogene 31, 1459–67, 2012
   PubMed Web of Science ®Google Scholar
• Raymond E, Hobday T, Castellano D, Reidy-Lagunes D, García-Carbonero R, Carrato A. Therapy innovations: tyrosine kinase inhibitors for the treatment of pancreatic neuroendocrine tumors. Cancer and Metastasis Reviews 30(Suppl 1), 19–26, 2011a
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine 364, 501–13, 2011b
   PubMed Web of Science ®Google Scholar
• *Reusch CE. Glucocorticoid therapy. In: Feldman EC, Nelson RW, Reusch CE, Scott-Moncrieff JCR (eds). Canine and Feline Endocrinology. 4th Edtn. Pp 555–77. Saunders, St. Louis, MO, USA, 2015
   Google Scholar
• *Rosol TJ, Meuten DJ. Tumors of the endocrine glands: tumors of the pancreatic islet cells. In: Meuten DJ (eds). Tumors in Domestic Animals. 5th Edtn. Pp 822–28. Iowa State University Press, Ames, IA, USA, 2016
   Google Scholar
• Tobin RL, Nelson RW, Lucroy MD, Wooldridge JD, Feldman EC. Outcome of surgical versus medical treatment of dogs with beta cell neoplasia: 39 cases (1990–1997). Journal of the American Veterinary Medical Association 215, 226–30, 1999
   PubMed Web of Science ®Google Scholar
• Urie BK, Russell DS, Kisseberth WC, London CA. Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma. BMC Veterinary Research 8, 67, 2012
   PubMed Web of Science ®Google Scholar
• * Non-peer-reviewed.
   Google Scholar